HOPA Volunteer Opportunities – Needs Assessment Workgroup, Program Committee, and Session Proposal Review Workgroup
HOPA is seeking qualified members for three important volunteer opportunities. The Needs Assessment Workgroup maintains and enhances HOPA’s needs assessment library, fueling future educational programming. The Program Committee coordinates the planning and development of the educational program at the 2016 HOPA Annual Conference. The Session Proposal Review Workgroup manages the call, review, and selection process for the 2016 conference sessions. The Needs Assessment Workgroup term will begin in March, with the Program Committee and Session Proposal Review Workgroup beginning in April 2015. Visit the Volunteer Activity Center for complete information and to express your interest.
Learn how you can support Provider Status.
2015 HOPA Annual Conference registration is now live! Find up-to-the minute conference and hotel information at Conference Web Central.
HOPA Oncology Pharmacists: Committed to the Care of Patients with Cancer
Check out the new educational video produced by HOPA explaining the critical role of the oncology pharmacist.
HOPA’s letter to Genentech CEO Ian Clark has generated a number of references in media coverage on the new distribution model. Here are two of the most recent:
Ascension Health Bans Genentech Sales Reps After Losing Drug Discounts
(PharmTech.com) Oct 7, 2014 - A change in the supply chain for three important Genentech cancer medications elicits a strong reaction from one of the nation's largest operators of hospitals. read article
Genentech Sales Reps Face Hospital Bans Over a Wholesale Change
(Wall Street Journal-Pharmalot) October 3, 2014 - Ascension Health, which is one of the nation’s largest operators of hospitals and clinics, has banned Genentech sales representatives from visiting its 1,900 hospitals and clinics around the country after the drug maker changed distribution for three big-selling cancer medicines earlier this week. read article
The HOPA Board of Directors submitted a letter to Genentech’s CEO Ian T. Clark, addressing the impact that a new distribution model will have on cancer care. Additionally, HOPA, ACCC and other organizations sent a joint letter outlining their concerns.
HOPA has been involved in conversations with Genentech in response to their change in distribution channels for its infused cancer medicines. HOPA continues to closely monitor the situation and provide additional information as it becomes available. If you have specific reports of interruptions in patient care, please contact HOPA at email@example.com with the subject line “Genentech”.
Read Genentechs response to concerns raised by HOPA.